A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
Conditions: Metastatic Non-small Cell Lung Cancer (NSCLC); Non-squamous NSCLC Interventions: Drug: ABP 215; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin Sponsors: Amgen; Parexel Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | China Health | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study